This new partnership will see the distribution of the Company’s standardized, naturally derived, psilocybin containing mushrooms for therapeutic use at Atman retreats in Jamaica
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has entered into a supply partnership (the “Supply Partnership”) with Atman Retreat, a retreat center helping people to explore psychedelics therapeutically, in order to harness the potential of healing, transformation, and transcendental experience.
Pursuant to the Supply Partnership, HAVN Life will supply naturally derived psilocybin for use during Atman Retreat programs, which operate in compliance with local and international protocols. HAVN Life will provide Atman from its facility in Jamaica, where mushrooms are cultivated under GACP and processed in a GMP facility, with a product that ensures greater consistency and more accurate dosing, as well as better quality control compared to alternative local sources.
The first shipments to Atman are scheduled to be delivered in May 2022 to support retreats that are already scheduled.
“Our Supply Partnership with Atman Retreat is a natural fit,” says Dr. Ivan Casselman, Chief Psychedelic Officer at HAVN Life. “For the past year, HAVN Labs has been working towards developing a global supply of psilocybin mushrooms and related products. In addition to our local partnerships with Hypha Wellness and GMP manufacturer P.A. Benjamin, we are keen to support and collaborate with other companies within Jamaica’s psychedelic space – one that we believe has huge potential,” he adds.
“We are happy to partner with HAVN Life to ensure a reliable supply of high quality psilocybin mushrooms for our retreats,” says Aaron Nesmith-Beck, founder of Atman Retreat. “As access to the healing and transformative potential of psilocybin remains limited around the world, we are excited and honoured to continue providing safe psychedelic experiences at our retreats in Jamaica.”
HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin containing mushrooms, solidifying relationships with local partners.
On Behalf of The Board of Directors
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.
About Atman Retreat
Atman Retreat’s mission to help people explore the full potential of the psychedelic experience, in all its healing, transformative, and transcendent qualities. Atman Retreats are held in Jamaica, where psilocybin mushrooms are legal. Participants stay at a spacious villa, with comfortable rooms and a scenic private beachfront. The Atman team of experienced facilitators is passionate about creating space for inner transformation, insight, and breakthroughs. Atman Retreat is a complete 4-day experience that allows participants to explore psychedelics safely, legally, and in a setting designed to maximize their benefits.
Investor Relations: firstname.lastname@example.org
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Supply Partnership, product specifications, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipated benefits of the Supply Partnership will not be realized as contemplated, or at all, risks that the products manufactured at the Company’s facilities will not meet the stated product specifications, and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.